Nishadil
Signup Signin
Delhi | 25°C (windy)
CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future

CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future
The Unyielding Riddle of Alzheimer's: Why Progress Feels So Elusive

The Unyielding Riddle of Alzheimer's: Why Progress Feels So Elusive
Decoding Chase Coleman's Latest Bets: A Deep Dive into Tiger Global's Q3 2025 Portfolio Shifts

Decoding Chase Coleman's Latest Bets: A Deep Dive into Tiger Global's Q3 2025 Portfolio Shifts
CureVac's Crossroads: Why Wall Street Is Treading Carefully Towards 2026

CureVac's Crossroads: Why Wall Street Is Treading Carefully Towards 2026
The Unstoppable Surge: S&P 500 Earnings Power Through, Shaking Off Skepticism

The Unstoppable Surge: S&P 500 Earnings Power Through, Shaking Off Skepticism
Beyond the Noise: How Polen Global Growth Finds True Value in a Shifting World

Beyond the Noise: How Polen Global Growth Finds True Value in a Shifting World
Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment

Cagrisema: Novo Nordisk's Dual-Action Powerhouse Poised to Revolutionize Obesity Treatment
The Drumbeat of Disinflation: Why the Federal Reserve is Poised to Cut Rates Once More

The Drumbeat of Disinflation: Why the Federal Reserve is Poised to Cut Rates Once More
Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope

Healthcare Shorts Take a Breather, But Moderna Remains Under the Microscope
The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance
Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market

Metsera: The New Power Player Set to Disrupt the $100 Billion GLP-1 Market
Load more..